Targeted therapies, particularly tyrosine kinase inhibitors (TKI) dominate the treatment of advanced/metastatic renal cell carcinoma (mRCC) in the first line.
While new drugs have expanded the treatment options, mRCC remains incurable, and most first-line patients relapse following treatment. Significant opportunities remain for new therapies under development in this highly competitive market.
Capitalizing on our unique expertise in the mRCC market and in patient chart-based research, mRCCsyndiTrackTM, our mRCC syndicated study uses real world data to monitor the evolution of mRCC management.Example of recent release:
- Data from Dec20 in FR, UK, DE, ES, IT
- 351 Onco-Hematologists
- 2,083 real-world patient charts analyzed
More information about our mRCC syndicated study?
- Types of data collected
- Dates of research waves
Fill in the form and we will be in touch shortly. 👉